{"pub": "reuters", "url": "https://uk.reuters.com/article/uk-astrazeneca-farxiga-fda/u-s-fda-approves-astrazenecas-diabetes-drug-for-treating-heart-failure-risk-idUKKBN1X00JC", "downloaded_at": "2019-10-21 06:43:00.145196+00:00", "title": "U.S. FDA approves AstraZeneca's diabetes drug for treating heart failure risk", "language": "en", "text": "FILE PHOTO: A man walks past a sign at an AstraZeneca site in Macclesfield, England May 19, 2014. REUTERS/Phil Noble/File Photo\n\n(Reuters) - AstraZeneca Plc (AZN.L) said on Monday U.S. regulators approved its diabetes drug Farxiga to be used as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks.\n\nThe approval by the U.S. Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial, the British drugmaker said and follows a similar approval here by the European authorities in August.\n\nDiabetes is associated with a high risk of heart failure.", "description": "AstraZeneca Plc said on Monday U.S. regulators approved its diabetes drug Farxiga to be used as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks.", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s3.reutersmedia.net/resources/r/?m=02&d=20191021&t=2&i=1443247992&w=1200&r=LYNXMPEF9K0CQ", "published_at": "2019-10-21"}